Tools and paradigms for non-invasive precision cancer management
The Sheybani Lab at the University of Virginia is working at the nexus of therapeutic ultrasound, advanced imaging, and tumor immunology to design and deploy precision cancer immunotherapy paradigms. The group seeks to advance the role of focused ultrasound (FUS) for immuno-modulation and immunotherapy delivery in solid cancers of the brain and periphery.
SELECTED PUBLICATIONS
-
Profiling of the Tumor-Immune Landscape in Murine Glioblastoma following Blood Brain/Tumor Barrier Disruption with MR Image-guided Focused Ultrasound
Glioblastoma (GB) poses formidable challenges to systemic immunotherapy approaches owing to the paucity of immune infiltration and presence of the blood brain/tumor barriers (BBB/BTB).
-
Functional Intersections Between Extracellular Vesicles and Oncolytic Therapies
Minimally invasive focal therapies for nonviral oncolysis are a cornerstone of cancer therapeutics. Our ability to optimally deploy oncolytic therapies and identify synergistic combination approaches requires a deeper understanding of elicited biological responses.
-
ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma
Phagocytic immunotherapies such as CD47 blockade have emerged as promising strategies for glioblastoma (GB) therapy, but the blood brain/tumor barriers (BBB/BTB) pose a persistent challenge for mCD47 delivery that can be overcome by focused ultrasound (FUS)-mediated BBB/BTB disruption.
MORE ABOUT US
-
Focused Ultrasound Cancer Immunotherapy Center at the University of Virginia
Our mission is to differentiate UVA as the worldwide leader in translational FUS immuno-oncology research.
-
Latest News
Twitter is a great place to find the latest news about Dr. Sheybani and the lab.